Impact of intracoronary adenosine on the no-reflow phenomenon: A randomized, triple-blind, placebo-controlled clinical trial
Prophylactic intracoronary adenosine did not significantly reduce angiographic no-reflow in STEMI patients undergoing primary PCI but was associated with greater left ventricular functional recovery at 40 days. These findings suggest a cardioprotective effect of adenosine on the microvasculature and myocardial tissue, supporting its potential role as an adjunctive therapy in STEMI management.
Authors
- Saman Parvaneh
- Fatemeh Baharvand (ORCID: https://orcid.org/0000-0003-2285-2688)
- Mohammadreza Aghajankhah
- Bahare Gholami Chaboki (ORCID: https://orcid.org/0000-0002-2793-5178)
- Francesca Maria Di Muro (ORCID: https://orcid.org/0000-0002-2145-6555)
Institutions
- Guilan University of Medical Sciences (IR)
- Cardiovascular Institute of the South (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- American Heart Journal Plus Cardiology Research and Practice
- Published
- 2025-10-21
- DOI
- https://doi.org/10.1016/j.ahjo.2025.100650
- Citations
- 1
- Primary Topic
- Cardiac Ischemia and Reperfusion
- Type
- article
- Field-Weighted Citation Impact
- 1.47